According to the European Commission’s Notice C (2020) 9264 on the Application of the Union’s pharmaceutical acquis in markets historically dependent on medicines supply from or through Great Britain after the end of the transition period, as of 1st January 2021, packs destined for Great Britain should be separated from packs destined for Cyprus, Ireland, Malta or Northern Ireland – even where the supply route goes through Great Britain. This means that manufacturers and marketing authorisation holders will need to ensure the upload of the required data in the EMVS for all packs bearing the safety features, specifically the serial number, destined for either the GB, NI, CY, MT and IE markets.